Quest Diagnostics (DGX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues reached $2.49 billion, up 8.5% year-over-year, with 4.2% organic growth, driven by new customer wins, expanded business, and recent acquisitions including LifeLabs, Allina Health, and three NY physician group labs.

• Reported diluted EPS for Q3 was $1.99, up 1.5% year-over-year; adjusted diluted EPS was $2.30, up 3.6% year-over-year.

• Net income attributable to Quest Diagnostics was $226 million, up 0.5% from Q3 2023; adjusted net income was $262 million.

• Advanced diagnostics, automation, and AI initiatives contributed to operational improvements and productivity gains.

• Consumer-initiated testing platform revenue grew over 40%, with repeat customer rates rising to 30%.

Financial highlights

• Q3 consolidated revenues were $2.49 billion, up 8.5% year-over-year; organic revenues grew 4.2%.

• Diagnostic Information Services (DIS) revenues increased 9% year-over-year, with volume up 5.5% and revenue per requisition up 3.3%.

• Operating income for Q3 was $330 million (13.3% margin); adjusted operating income was $385 million (15.5% margin).

• Net cash provided by operating activities for the nine months ended September 30, 2024 was $870 million, up 17% year-over-year.

• Capital expenditures for the nine months were $302 million; full-year expected at $420 million.

Outlook and guidance

• 2024 revenue guidance raised to $9.8–$9.85 billion, driven by acquisitions.

• Reported EPS expected at $7.55–$7.70; adjusted EPS at $8.85–$8.95.

• Cash from operations projected at $1.3 billion; capital expenditures at $420 million.

• Operating margin expected to be down year-over-year due to LifeLabs integration and weather/IT headwinds, but up excluding these impacts.

• Hurricane Milton is projected to negatively impact Q4 net revenues by ~$15 million and EPS by ~$0.08.